A Study on 102 Inpatients with Idiopathic Sudden Sensorineural Hearing Loss

抄録

One hundred two inpatients with idiopathic sudden sensorineural hearing loss (ISSHL) treated primarily in our hospital between January 2008 and March 2014 were studied clinico-statistically. Our principal therapy adopted for ISSHL included a series of glucocorticoids, methylprednisolone sodium succinate, or prednisolone sodium succinate.
The treatment results were as follows; the cure, improvement, and effective ratios were 32.4%, 54.9%, and 76.5%, respectively. According to the grades for initial hearing levels, the cure ratios were not statistically different. The ratios differed based on the types of audiogram, especially for the deaf or completely deaf types; however, no cured cases were identified. Patients >64 years of age at the first presentation had significantly lower ratios than patients <64 years of age. In addition, patients complaining of vertigo had significantly lower ratios than those without vertigo. Amongst the patients with diabetes mellitus (DM), the cure ratio was not significantly different from patients without DM because insulin was administered immediately after admission. There were no significant differences in the efficacies of the different types of glucocorticoids in the treatment of ISSHL, thus we decided to administer prednisolone sodium succinate because of the lower cost, as analyzed with a clinical pathway. Stellate ganglion block (SGB) therapy did not contribute to the therapy for ISSHL, but in patients with less than grade 3 ISSHL, the, effectiveness was significant.